Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Onalespib in EGFR-Mutant NSCLC
NCT02535338Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onalespib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Apr 2016; status: completed.
02
Drugs
onalespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02535338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535338.